Palisade Bio (PALI) Change in Accured Expenses (2010 - 2026)
Palisade Bio (PALI) reported Change in Accured Expenses of $2.6 million for Q1 2026, up 524.17% year-over-year from $410463.7 in Q1 2025, and up 278.43% on a QoQ basis from $677000.0 in Q4 2025.
Palisade Bio (PALI) has 17 years of Change in Accured Expenses data on file, last reported at $2.6 million in Q1 2026.
- Quarterly Change in Accured Expenses rose 524.17% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 million (up 4038.95% YoY) and the FY2025 annual result came in at $576000.0, up 1128.57% from the prior year.
- Change in Accured Expenses climbed to $2.6 million in Q1 2026 per PALI's latest filing, from $677000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $2.6 million in Q1 2026 and bottomed at -$1.3 million in Q3 2025.
- The 5-year median for Change in Accured Expenses is $100000.0 (2023), against an average of $175823.5.
- Peak annual rise in Change in Accured Expenses reached 2318.67% in 2025, while the deepest fall reached 914.29% in 2025.
- Tracing PALI's Change in Accured Expenses over 5 years: stood at -$307000.0 in 2022, then plunged by 74.27% to -$535000.0 in 2023, then jumped by 151.03% to $273000.0 in 2024, then soared by 147.99% to $677000.0 in 2025, then surged by 278.43% to $2.6 million in 2026.
- Per Business Quant, the three latest PALI Change in Accured Expenses figures stand at $2.6 million (Q1 2026), $677000.0 (Q4 2025), and -$1.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | 2.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.56 Mn |
| Mar 31, 2026 | 2.56 Mn |
| Dec 31, 2025 | 677,000.00 |
| Dec 31, 2025 | 677,000.00 |
| Sep 30, 2025 | -1.31 Mn |
| Sep 30, 2025 | -1.31 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Mar 31, 2025 | -604,000.00 |
| Mar 31, 2025 | -604,000.00 |
| Dec 31, 2024 | 273,000.00 |
| Dec 31, 2024 | 273,000.00 |
| Sep 30, 2024 | 161,000.00 |
| Sep 30, 2024 | 161,000.00 |
| Jun 30, 2024 | 75,000.00 |
| Jun 30, 2024 | 75,000.00 |
| Mar 31, 2024 | -565,000.00 |
| Mar 31, 2024 | -565,000.00 |
| Dec 31, 2023 | -535,000.00 |
| Dec 31, 2023 | -535,000.00 |
| Sep 30, 2023 | 238,000.00 |
| Sep 30, 2023 | 238,000.00 |
| Jun 30, 2023 | 100,000.00 |
| Jun 30, 2023 | 100,000.00 |
| Mar 31, 2023 | -295,000.00 |
| Mar 31, 2023 | -295,000.00 |
| Dec 31, 2022 | -307,000.00 |
| Dec 31, 2022 | -307,000.00 |
| Sep 30, 2022 | 536,000.00 |
| Sep 30, 2022 | 536,000.00 |
| Jun 30, 2022 | 229,000.00 |
| Jun 30, 2022 | 229,000.00 |
| Mar 31, 2022 | -59,000.00 |
| Mar 31, 2022 | -59,000.00 |
| Dec 31, 2021 | -851,000.00 |
| Dec 31, 2021 | -851,000.00 |
| Sep 30, 2021 | 589,000.00 |
| Sep 30, 2021 | 589,000.00 |
| Jun 30, 2021 | -2.13 Mn |
| Jun 30, 2021 | -2.13 Mn |
| Mar 31, 2021 | -8,000.00 |
| Mar 31, 2021 | -8,000.00 |
| Dec 31, 2020 | 195,000.00 |
| Dec 31, 2020 | 195,000.00 |
| Sep 30, 2020 | 301,000.00 |
| Sep 30, 2020 | 301,000.00 |
| Jun 30, 2020 | 996,958.00 |
| Jun 30, 2020 | 996,958.00 |
| Mar 31, 2020 | 1,042.00 |
| Mar 31, 2020 | 1,042.00 |
| Dec 31, 2019 | 183,796.00 |
| Dec 31, 2019 | 183,796.00 |
| Sep 30, 2019 | 8,081.00 |
| Sep 30, 2019 | 8,081.00 |
| Jun 30, 2019 | -300,510.00 |
| Jun 30, 2019 | -300,510.00 |
| Mar 31, 2019 | 244,319.00 |
| Mar 31, 2019 | 244,319.00 |
| Dec 31, 2018 | -11,504.00 |
| Dec 31, 2018 | -11,504.00 |
| Sep 30, 2018 | -67,177.00 |
| Sep 30, 2018 | -67,177.00 |
| Jun 30, 2018 | 49,059.00 |
| Jun 30, 2018 | 49,059.00 |
| Mar 31, 2018 | -7,369.00 |
| Mar 31, 2018 | -7,369.00 |
| Dec 31, 2017 | -1.33 Mn |
| Dec 31, 2017 | -1.33 Mn |
| Sep 30, 2017 | -35,391.00 |
| Sep 30, 2017 | -35,391.00 |
| Jun 30, 2017 | 692,222.00 |
| Jun 30, 2017 | 692,222.00 |
| Mar 31, 2017 | -852,963.00 |
| Mar 31, 2017 | -852,963.00 |
| Dec 31, 2016 | 852,963.00 |
| Dec 31, 2016 | 852,963.00 |
| Sep 30, 2016 | -102,722.00 |
| Sep 30, 2016 | -102,722.00 |
| Jun 30, 2016 | -107,817.00 |
| Jun 30, 2016 | -107,817.00 |
| Mar 31, 2016 | 49,177.00 |
| Mar 31, 2016 | 49,177.00 |
| Dec 31, 2015 | -606,627.00 |
| Dec 31, 2015 | -606,627.00 |
| Sep 30, 2015 | 277,240.00 |
| Sep 30, 2015 | 277,240.00 |
| Jun 30, 2015 | 219,777.00 |
| Jun 30, 2015 | 219,777.00 |
| Mar 31, 2015 | -375,988.00 |
| Mar 31, 2015 | -375,988.00 |
| Dec 31, 2014 | -5,397.00 |
| Dec 31, 2014 | -5,397.00 |
| Sep 30, 2014 | 1,935.00 |
| Sep 30, 2014 | 1,935.00 |
| Jun 30, 2014 | 308,667.00 |
| Jun 30, 2014 | 308,667.00 |
| Mar 31, 2014 | -307,411.00 |
| Mar 31, 2014 | -307,411.00 |
| Dec 31, 2013 | 21,010.00 |
| Dec 31, 2013 | 21,010.00 |
| Sep 30, 2013 | -19,760.00 |
| Sep 30, 2013 | -19,760.00 |
| Jun 30, 2013 | 12,540.00 |
| Jun 30, 2013 | 12,540.00 |
| Mar 31, 2013 | -11,321.00 |
| Mar 31, 2013 | -11,321.00 |
| Dec 31, 2012 | 366,648.00 |
| Dec 31, 2012 | 366,648.00 |
| Sep 30, 2012 | -220,361.00 |
| Sep 30, 2012 | -220,361.00 |
| Jun 30, 2012 | -121,978.00 |
| Jun 30, 2012 | -121,978.00 |
| Dec 31, 2011 | 801,944.00 |
| Dec 31, 2011 | 801,944.00 |
| Sep 30, 2011 | 268,731.00 |
| Sep 30, 2011 | 268,731.00 |
| Jun 30, 2011 | 47,720.00 |
| Jun 30, 2011 | 47,720.00 |
| Mar 31, 2011 | -230,143.00 |
| Mar 31, 2011 | -230,143.00 |
| Dec 31, 2010 | 224,460.00 |
| Dec 31, 2010 | 224,460.00 |
| Sep 30, 2010 | 169,987.00 |
| Sep 30, 2010 | 169,987.00 |